Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

Candida glabrata

  • Activity of a Novel 1,3-Beta-<span class="sc">d</span>-Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against <em>Candida glabrata</em>
    Susceptibility
    Activity of a Novel 1,3-Beta-d-Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata

    Ibrexafungerp (formerly SCY-078), a novel glucan synthase inhibitor with oral availability, was evaluated for activity against Candida glabrata. The susceptibility of clinical strains to ibrexafungerp was determined by microdilution and time-kill assays. The MIC range against wild-type strains was 1 to 2 μg/ml. Ibrexafungerp was also active against the majority of...

    M. Ghannoum, L. Long, N. Isham, C. Hager, R. Wilson, K. Borroto-Esoda, S. Barat, D. Angulo
  • <em>In Vitro</em> Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against <span class="named-content genus-species" id="named-content-1">Candida glabrata</span> Isolates with <em>FKS</em> Mutations
    Susceptibility
    In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations

    Ibrexafungerp is a first-in-class glucan synthase inhibitor. In vitro activity was determined for 89 Candida glabrata isolates with molecularly identified FKS1 or FKS2 mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin, caspofungin, or micafungin) by broth...

    Natalie S. Nunnally, Kizee A. Etienne, David Angulo, Shawn R. Lockhart, Elizabeth L. Berkow
  • Impact of the Major <span class="named-content genus-species" id="named-content-1">Candida glabrata</span> Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161
    Mechanisms of Resistance
    Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161

    VT-1161 and VT-1598 are promising investigational tetrazole antifungals that have shown in vitro and in vivo activity against Candida and other fungi. Candida glabrata is a problematic opportunistic pathogen that is associated with high mortality in invasive infection, as well as both intrinsic and rapidly acquired antifungal resistance....

    Andrew T. Nishimoto, Sarah G. Whaley, Nathan P. Wiederhold, Qing Zhang, Christopher M. Yates, William J. Hoekstra, Robert J. Schotzinger, Edward P. Garvey, P. David Rogers
  • Free
    Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for <em>FKS</em>-Associated Echinocandin Resistance in <span class="named-content genus-species" id="named-content-1">Candida glabrata</span> Septic Arthritis and Osteomyelitis
    Challenging Clinical Case in Antimicrobial Resistance
    Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for FKS-Associated Echinocandin Resistance in Candida glabrata Septic Arthritis and Osteomyelitis

    We report the case of a 61-year-old female with Crohn’s disease dependent on total parenteral nutrition who developed a central venous catheter bloodstream infection and septic arthritis, complicated further by osteomyelitis and persistent Candida glabrata fungemia. Fluconazole treatment led to persistent infection, and micafungin therapy failed with development of...

    William F. Wright, Nika Bejou, Ryan K. Shields, Kieren Marr, Todd P. McCarty, Peter G. Pappas
  • Open Access
    Low Level of Antifungal Resistance in Iranian Isolates of <span class="named-content genus-species" id="named-content-1">Candida glabrata</span> Recovered from Blood Samples in a Multicenter Study from 2015 to 2018 and Potential Prognostic Values of Genotyping and Sequencing of <em>PDR1</em>
    Mechanisms of Resistance
    Low Level of Antifungal Resistance in Iranian Isolates of Candida glabrata Recovered from Blood Samples in a Multicenter Study from 2015 to 2018 and Potential Prognostic Values of Genotyping and Sequencing of PDR1

    Establishing an effective empirical antifungal therapy requires that national surveillance studies be conducted. Herein, we report the clinical outcome of infections with and the microbiological features of Iranian isolates of Candida glabrata derived from patients suffering from candidemia.

    ...
    Amir Arastehfar, Farnaz Daneshnia, Kamiar Zomorodian, Mohammad Javad Najafzadeh, Sadegh Khodavaisy, Hossein Zarrinfar, Ferry Hagen, Zahra Zare Shahrabadi, Michaela Lackner, Hossein Mirhendi, Mohammadreza Salehi, Maryam Roudbary, Weihua Pan, Markus Kostrzewa, Teun Boekhout
  • Inhibition of Vesicular Transport Influences Fungal Susceptibility to Fluconazole
    Mechanisms of Resistance
    Inhibition of Vesicular Transport Influences Fungal Susceptibility to Fluconazole

    Fungal infections pose a substantial threat to the human population. They can cause either mild and relatively harmless infections or invasive and often lethal diseases in patients with a weakened immune system.

    Liesbeth Demuyser, Katrien Van Dyck, Bea Timmermans, Patrick Van Dijck
  • Open Access
    <em>In Vitro</em> Activity of a Novel Antifungal Compound, MYC-053, against Clinically Significant Antifungal-Resistant Strains of <em>Candida glabrata</em>, <em>Candida auris</em>, <em>Cryptococcus neoformans</em>, and <em>Pneumocystis</em> spp.
    Experimental Therapeutics
    In Vitro Activity of a Novel Antifungal Compound, MYC-053, against Clinically Significant Antifungal-Resistant Strains of Candida glabrata, Candida auris, Cryptococcus neoformans, and Pneumocystis spp.

    An urgent need exists for new antifungal compounds to treat fungal infections in immunocompromised patients. The aim of the current study was to investigate the potency of a novel antifungal compound, MYC-053, against the emerging yeast and yeast-like pathogens Candida glabrata, Candida auris,...

    G. Tetz, M. Collins, D. Vikina, V. Tetz
  • Detection of Echinocandin-Resistant <em>Candida glabrata</em> in Blood Cultures Spiked with Different Percentages of <em>FKS2</em> Mutants
    Susceptibility
    Detection of Echinocandin-Resistant Candida glabrata in Blood Cultures Spiked with Different Percentages of FKS2 Mutants

    Infections caused by the coexistence of Candida glabrata echinocandin-resistant and echinocandin-susceptible cells may be possible, and the detection of FKS mutants when the proportions of FKS mutants are underrepresented poses a problem. We assessed the role of EUCAST and methods directly performed on positive blood cultures—Etest (ETDIR...

    María Ángeles Bordallo-Cardona, Carlos Sánchez-Carrillo, Emilio Bouza, Patricia Muñoz, Pilar Escribano, Jesús Guinea
  • Comparative Genomics of Serial <em>Candida glabrata</em> Isolates and the Rapid Acquisition of Echinocandin Resistance during Therapy
    Mechanisms of Resistance
    Comparative Genomics of Serial Candida glabrata Isolates and the Rapid Acquisition of Echinocandin Resistance during Therapy

    The opportunistic pathogen Candida glabrata shows a concerning increase in drug resistance. Here, we present the analysis of two serial bloodstream isolates, obtained 12 days apart.

    Amelia E. Barber, Michael Weber, Kerstin Kaerger, Jörg Linde, Hanna Gölz, Daniel Duerschmied, Antonie Markert, Reinhard Guthke, Grit Walther, Oliver Kurzai
  • <em>ERG6</em> and <em>ERG2</em> Are Major Targets Conferring Reduced Susceptibility to Amphotericin B in Clinical <em>Candida glabrata</em> Isolates in Kuwait
    Mechanisms of Resistance
    ERG6 and ERG2 Are Major Targets Conferring Reduced Susceptibility to Amphotericin B in Clinical Candida glabrata Isolates in Kuwait

    Candida glabrata is intrinsically less susceptible to azoles, and resistance to echinocandins and reduced susceptibility (RS) to amphotericin B (AMB) have also been detected. The molecular mechanisms of RS to AMB were investigated in C. glabrata strains in Kuwait by sequence analyses of genes...

    Suhail Ahmad, Leena Joseph, Josie E. Parker, Mohammad Asadzadeh, Steven L. Kelly, Jacques F. Meis, Ziauddin Khan

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596